Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 18, 2002
- Market Must Be Attractive to Invite Investment from Abroad: JPMA President
November 18, 2002
- Bill for Law on IP Presented to Lower House
November 18, 2002
- Yamanouchi: Record-high Sales, Operating Profits Attributable to Harnal, Lipitor
November 18, 2002
- Drug Substitution by Pharmacists to Become Major Topic
November 18, 2002
- Eisai: Pariet, Aricept Contribute to Good Sales, Profits
November 18, 2002
- BUSINESS NEWS IN BRIEF
November 18, 2002
- Semi-annual Business Results
November 18, 2002
- WEBSITE NEWS
November 18, 2002
- Pramipexole Reported as 1st-Line Treatment for Parkinson's Disease
November 18, 2002
- Azwell Taking Tougher Stance in Price Negotiations
November 18, 2002
- Boehringer Ingelheim, ImmunoGen Start Trial on New Anticancer Agent
November 18, 2002
- JPMA Exchanges Opinions with ABPI, SNIP
November 18, 2002
- Zyvox Effective against Diabetic Foot Infections: Pharmacia
November 18, 2002
- New Chugai Is Enjoying Synergism: President Nagayama
November 18, 2002
- Over 100 Mil. Prescriptions Issued for Pharmacia's Xalatan
November 18, 2002
- Consumers Want More Info from Drug Makers: JPMA Survey
November 18, 2002
- GSK Reports Results of Major Survey on COPD
November 18, 2002
- MPC: Merger Synergism Boosts Sales, Profits
November 18, 2002
- DIAGNOSTIC NEWS IN BRIEF
November 18, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…